{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:54:27Z","timestamp":1781628867659,"version":"3.54.5"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine project","award":["712023001;712023002;712024001"],"award-info":[{"award-number":["712023001;712023002;712024001"]}]},{"name":"Project of Science and Technology Program of Tianjin","award":["24ZXZSSS00480, 24ZYCGSY00640"],"award-info":[{"award-number":["24ZXZSSS00480, 24ZYCGSY00640"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2019-I2M-5-020"],"award-info":[{"award-number":["2019-I2M-5-020"]}]},{"name":"Tianjin Health Science and Technology Project","award":["TJWJ2023QN034"],"award-info":[{"award-number":["TJWJ2023QN034"]}]},{"name":"Tianjin Science and Technology Project","award":["24JCYBJC01840"],"award-info":[{"award-number":["24JCYBJC01840"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82372194 and 82204546"],"award-info":[{"award-number":["82372194 and 82204546"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Cholangiocarcinoma (CCA) is a highly aggressive biliary malignancy with a very poor prognosis. How to screen the optimal chemotherapy regimen is crucial for enhancing the prognosis of CCA patients. The study aims to develop patient-derived tumor organoid (PDO) models and patient-derived tumor xenograft (PDX) models of CCA to simulate clinical responses to chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Tumor tissues were collected from patients undergoing surgical resection and subsequently utilized to establish PDO and PDX models. Hematoxylin-eosin (H&amp;E), immunohistology (IHC), and immunofluorescence (IF) were conducted to analyze the biological characteristics of these PDXs and PDOs. Whole exome sequencing (WES) was performed to identify the mutation types of primary tumor, PDO, and PDX. Drug sensitivity assays were conducted utilizing PDO and PDX models to compare clinical treatment responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In this study, we successfully established 18 PDO (success rate, 56.3%) models and 21 PDX models (success rate, 65.6%) from 32 patients diagnosed with CCA. PDO and PDX preserved the mutational profiles characteristic of the primary tumor samples. The drug screening results from PDOs demonstrated a correlation with the actual clinical response to chemotherapy regimens, and these findings were further validated in PDX models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings indicate that the integration of PDO and PDX models can successfully guide clinical treatment strategies, facilitating effective personalized therapy for CCA patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-025-15495-w","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T03:23:07Z","timestamp":1767151387000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Individualized drug screening in cholangiocarcinoma using organoid models and patient-derived tumor xenograft"],"prefix":"10.1186","volume":"26","author":[{"given":"Pinsheng","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuyang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongdeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianze","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"issue":"9","key":"15495_CR1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Reviews Gastroenterol Hepatol. 2020;17(9):557\u201388.","journal-title":"Nat Reviews Gastroenterol Hepatol"},{"issue":"1","key":"15495_CR2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","volume":"7","author":"PJ Brindley","year":"2021","unstructured":"Brindley PJ, Bachini M, Ilyas SI, Khan SA, Loukas A, Sirica AE, et al. Cholangiocarcinoma. Nat Reviews Disease Primers. 2021;7(1):65.","journal-title":"Nat Reviews Disease Primers"},{"issue":"9935","key":"15495_CR3","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","volume":"383","author":"N Razumilava","year":"2014","unstructured":"Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet (London England). 2014;383(9935):2168\u201379.","journal-title":"Lancet (London England)"},{"issue":"2","key":"15495_CR4","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3322\/caac.21759","volume":"73","author":"D Moris","year":"2023","unstructured":"Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME. Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians. Cancer J Clin. 2023;73(2):198\u2013222.","journal-title":"Cancer J Clin"},{"issue":"5","key":"15495_CR5","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.jhep.2021.12.010","volume":"76","author":"L Izquierdo-Sanchez","year":"2022","unstructured":"Izquierdo-Sanchez L, Lamarca A, La Casta A, Buettner S, Utpatel K, Kl\u00fcmpen HJ, et al. Cholangiocarcinoma landscape in europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA registry. J Hepatol. 2022;76(5):1109\u201321.","journal-title":"J Hepatol"},{"issue":"2","key":"15495_CR6","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jhep.2019.10.009","volume":"72","author":"RK Kelley","year":"2020","unstructured":"Kelley RK, Bridgewater J, Gores GJ, Zhu AX. Systemic therapies for intrahepatic cholangiocarcinoma. J Hepatol. 2020;72(2):353\u201363.","journal-title":"J Hepatol"},{"issue":"2","key":"15495_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","volume":"15","author":"SI Ilyas","year":"2018","unstructured":"Ilyas SI, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Reviews Clin Oncol. 2018;15(2):95\u2013111.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"11","key":"15495_CR8","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41571-022-00682-6","volume":"19","author":"ER Zanella","year":"2022","unstructured":"Zanella ER, Grassi E, Trusolino L. Towards precision oncology with patient-derived xenografts. Nat Reviews Clin Oncol. 2022;19(11):719\u201332.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"7","key":"15495_CR9","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.stem.2023.05.012","volume":"30","author":"HHN Yan","year":"2023","unstructured":"Yan HHN, Chan AS, Lai FP, Leung SY. Organoid cultures for cancer modeling. Cell Stem Cell. 2023;30(7):917\u201337.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"15495_CR10","doi-asserted-by":"publisher","first-page":"8571","DOI":"10.36922\/or.8571","volume":"1","author":"Z Shichao","year":"2025","unstructured":"Shichao Z. Patient-derived tumor organoids-guided adjuvant chemotherapy after surgical resection of intrahepatic cholangiocarcinoma: A multicenter and retrospective study. OR. 2025;1(1):8571.","journal-title":"OR"},{"issue":"11","key":"15495_CR11","doi-asserted-by":"publisher","first-page":"101277","DOI":"10.1016\/j.xcrm.2023.101277","volume":"4","author":"X Ren","year":"2023","unstructured":"Ren X, Huang M, Weng W, Xie Y, Wu Y, Zhu S, et al. Personalized drug screening in patient-derived organoids of biliary tract cancer and its clinical application. Cell Rep Med. 2023;4(11):101277.","journal-title":"Cell Rep Med"},{"issue":"11","key":"15495_CR12","first-page":"e2003897","volume":"8","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Li ZX, Zhu YJ, Fu J, Zhao XF, Zhang YN, et al. Single-Cell transcriptome analysis uncovers intratumoral heterogeneity and underlying mechanisms for drug resistance in hepatobiliary tumor Organoids. Advanced science (Weinheim. Baden-Wurttemberg Germany). 2021;8(11):e2003897.","journal-title":"Baden-Wurttemberg Germany)"},{"issue":"22","key":"15495_CR13","first-page":"e2105810","volume":"9","author":"W Wang","year":"2022","unstructured":"Wang W, Yuan T, Ma L, Zhu Y, Bao J, Zhao X, et al. Hepatobiliary tumor organoids reveal HLA class I neoantigen landscape and antitumoral activity of neoantigen peptide enhanced with immune checkpoint inhibitors. Adv Sci (Weinheim Baden-Wurttemberg Germany). 2022;9(22):e2105810.","journal-title":"Adv Sci (Weinheim Baden-Wurttemberg Germany)"},{"issue":"706","key":"15495_CR14","doi-asserted-by":"publisher","first-page":"eadg3358","DOI":"10.1126\/scitranslmed.adg3358","volume":"15","author":"S Ji","year":"2023","unstructured":"Ji S, Feng L, Fu Z, Wu G, Wu Y, Lin Y, et al. Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology. Sci Transl Med. 2023;15(706):eadg3358.","journal-title":"Sci Transl Med"},{"issue":"9","key":"15495_CR15","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","volume":"8","author":"H Tiriac","year":"2018","unstructured":"Tiriac H, Belleau P, Engle DD, Plenker D, Desch\u00eanes A, Somerville TDD, et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov. 2018;8(9):1112\u201329.","journal-title":"Cancer Discov"},{"key":"15495_CR16","doi-asserted-by":"publisher","first-page":"114751","DOI":"10.1016\/j.biopha.2023.114751","volume":"163","author":"M Zu","year":"2023","unstructured":"Zu M, Hao X, Ning J, Zhou X, Gong Y, Lang Y, et al. Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing. Biomed pharmacotherapy = Biomedecine Pharmacotherapie. 2023;163:114751.","journal-title":"Biomed pharmacotherapy = Biomedecine Pharmacotherapie"},{"key":"15495_CR17","doi-asserted-by":"publisher","first-page":"704042","DOI":"10.3389\/fonc.2021.704042","volume":"11","author":"Y Gao","year":"2021","unstructured":"Gao Y, Zhou R, Huang JF, Hu B, Cheng JW, Huang XW, et al. Patient-Derived xenograft models for intrahepatic cholangiocarcinoma and their application in guiding personalized medicine. Front Oncol. 2021;11:704042.","journal-title":"Front Oncol"},{"issue":"1","key":"15495_CR18","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41467-023-35896-4","volume":"14","author":"HS Lee","year":"2023","unstructured":"Lee HS, Han DH, Cho K, Park SB, Kim C, Leem G, et al. Integrative analysis of multiple genomic data from intrahepatic cholangiocarcinoma organoids enables tumor subtyping. Nat Commun. 2023;14(1):237.","journal-title":"Nat Commun"},{"issue":"4","key":"15495_CR19","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.celrep.2019.03.088","volume":"27","author":"Y Saito","year":"2019","unstructured":"Saito Y, Muramatsu T, Kanai Y, Ojima H, Sukeda A, Hiraoka N, et al. Establishment of Patient-Derived organoids and drug screening for biliary tract carcinoma. Cell Rep. 2019;27(4):1265\u2013e12761264.","journal-title":"Cell Rep"},{"key":"15495_CR20","doi-asserted-by":"crossref","unstructured":"Kinzler MN, Schulze F, Gretser S, Abedin N, Trojan J, Zeuzem S, et al. Expression of MUC16\/CA125 Is Associated with Impaired Survival in Patients with Surgically Resected Cholangiocarcinoma. Cancers. 2022;14(19):4703.","DOI":"10.3390\/cancers14194703"},{"key":"15495_CR21","doi-asserted-by":"crossref","unstructured":"Liu Y, Zhang Y, Zhu L, Zhou Z, Cui Y, Zhang H, Zhou C. PCLO is associated with tumor mutational burden and immunity in patients with oral squamous cell carcinoma. Curr Issues Mol Biol. 2025;47(6):426.","DOI":"10.3390\/cimb47060426"},{"issue":"2","key":"15495_CR22","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s43657-022-00062-1","volume":"3","author":"F Fu","year":"2023","unstructured":"Fu F, Tao X, Jiang Z, Gao Z, Zhao Y, Li Y, et al. Identification of germline mutations in East-Asian young Never-Smokers with lung adenocarcinoma by Whole-Exome sequencing. Phenomics. 2023;3(2):182\u20139.","journal-title":"Phenomics"},{"issue":"5","key":"15495_CR23","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.amjms.2019.07.012","volume":"358","author":"Y Liang","year":"2019","unstructured":"Liang Y, Jiang L, Zhong X, Hochwald SN, Wang Y, Huang L, et al. Discovery of aberrant alteration of genome in colorectal cancer by exome sequencing. Am J Med Sci. 2019;358(5):340\u20139.","journal-title":"Am J Med Sci"},{"issue":"5","key":"15495_CR24","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663\u201373.","journal-title":"Lancet Oncol"},{"issue":"5","key":"15495_CR25","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1080\/17474124.2021.1864325","volume":"15","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, Brandi G. BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care. Expert Rev Gastroenterol Hepatol. 2021;15(5):483\u20135.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"6","key":"15495_CR26","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.jhep.2022.07.022","volume":"77","author":"M Vithayathil","year":"2022","unstructured":"Vithayathil M, Khan SA. Current epidemiology of cholangiocarcinoma in Western countries. J Hepatol. 2022;77(6):1690\u20138.","journal-title":"J Hepatol"},{"issue":"1","key":"15495_CR27","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41392-023-01419-2","volume":"8","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wu W, Cai C, Zhang H, Shen H, Han Y. Patient-derived xenograft models in cancer therapy: technologies and applications. Signal Transduct Target Therapy. 2023;8(1):160.","journal-title":"Signal Transduct Target Therapy"},{"issue":"1","key":"15495_CR28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13045-022-01278-4","volume":"15","author":"H Xu","year":"2022","unstructured":"Xu H, Jiao D, Liu A, Wu K. Tumor organoids: applications in cancer modeling and potentials in precision medicine. J Hematol Oncol. 2022;15(1):58.","journal-title":"J Hematol Oncol"},{"key":"15495_CR29","doi-asserted-by":"publisher","first-page":"1043479","DOI":"10.3389\/fonc.2022.1043479","volume":"12","author":"D Tan","year":"2022","unstructured":"Tan D, An J, Gong M, Wang H, Li H, Meng H, et al. Screening of an individualized treatment strategy for an advanced gallbladder cancer using patient-derived tumor xenograft and organoid models. Front Oncol. 2022;12:1043479.","journal-title":"Front Oncol"},{"issue":"1","key":"15495_CR30","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13045-019-0829-z","volume":"13","author":"GJ Yoshida","year":"2020","unstructured":"Yoshida GJ. Applications of patient-derived tumor xenograft models and tumor organoids. J Hematol Oncol. 2020;13(1):4.","journal-title":"J Hematol Oncol"},{"key":"15495_CR31","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.copbio.2020.01.003","volume":"63","author":"F Invrea","year":"2020","unstructured":"Invrea F, Rovito R, Torchiaro E, Petti C, Isella C, Medico E. Patient-derived xenografts (PDXs) as model systems for human cancer. Curr Opin Biotechnol. 2020;63:151\u20136.","journal-title":"Curr Opin Biotechnol"},{"issue":"1","key":"15495_CR32","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12967-022-03405-8","volume":"20","author":"S Abdolahi","year":"2022","unstructured":"Abdolahi S, Ghazvinian Z, Muhammadnejad S, Saleh M, Asadzadeh Aghdaei H, Baghaei K. Patient-derived xenograft (PDX) models, applications and challenges in cancer research. J Translational Med. 2022;20(1):206.","journal-title":"J Translational Med"},{"issue":"8","key":"15495_CR33","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nrc3972","volume":"15","author":"RM Hoffman","year":"2015","unstructured":"Hoffman RM. Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts. Nat Rev Cancer. 2015;15(8):451\u20132.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"15495_CR34","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1182\/blood-2001-12-0207","volume":"100","author":"M Ito","year":"2002","unstructured":"Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, et al. NOD\/SCID\/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood. 2002;100(9):3175\u201382.","journal-title":"Blood"},{"issue":"10","key":"15495_CR35","doi-asserted-by":"publisher","first-page":"6477","DOI":"10.4049\/jimmunol.174.10.6477","volume":"174","author":"LD Shultz","year":"2005","unstructured":"Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, et al. Human lymphoid and myeloid cell development in NOD\/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. Journal of immunology (Baltimore, Md: 1950). 2005;174(10):6477\u20136489.","journal-title":"Journal of immunology (Baltimore, Md: 1950)"},{"issue":"12","key":"15495_CR36","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/nm.4438","volume":"23","author":"L Broutier","year":"2017","unstructured":"Broutier L, Mastrogiovanni G, Verstegen MM, Francies HE, Gavarr\u00f3 LM, Bradshaw CR, et al. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Nat Med. 2017;23(12):1424\u201335.","journal-title":"Nat Med"},{"issue":"12","key":"15495_CR37","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1002\/cac2.12224","volume":"41","author":"J Qu","year":"2021","unstructured":"Qu J, Kalyani FS, Liu L, Cheng T, Chen L. Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy. Cancer Commun (London England). 2021;41(12):1331\u201353.","journal-title":"Cancer Commun (London England)"},{"issue":"7","key":"15495_CR38","doi-asserted-by":"publisher","first-page":"e970","DOI":"10.1002\/ctm2.970","volume":"12","author":"Z Li","year":"2022","unstructured":"Li Z, Xu H, Yu L, Wang J, Meng Q, Mei H, et al. Patient-derived renal cell carcinoma organoids for personalized cancer therapy. Clin Translational Med. 2022;12(7):e970.","journal-title":"Clin Translational Med"},{"issue":"3","key":"15495_CR39","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.7150\/thno.63359","volume":"12","author":"A Teijeira","year":"2022","unstructured":"Teijeira A, Migueliz I, Garasa S, Karanikas V, Luri C, Cirella A, et al. Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers. Theranostics. 2022;12(3):1373\u201387.","journal-title":"Theranostics"},{"issue":"2","key":"15495_CR40","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1136\/gutjnl-2017-314549","volume":"68","author":"T Seidlitz","year":"2019","unstructured":"Seidlitz T, Merker SR, Rothe A, Zakrzewski F, von Neubeck C, Gr\u00fctzmann K, et al. Human gastric cancer modelling using organoids. Gut. 2019;68(2):207\u201317.","journal-title":"Gut"},{"issue":"1","key":"15495_CR41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41374-019-0298-6","volume":"100","author":"C Maletzki","year":"2020","unstructured":"Maletzki C, Bock S, Fruh P, Macius K, Witt A, Prall F, Linnebacher M. NSG mice as hosts for oncological precision medicine. Lab Invest. 2020;100(1):27\u201337.","journal-title":"Lab Invest"},{"issue":"11","key":"15495_CR42","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1158\/1078-0432.CCR-17-3490","volume":"24","author":"E Marangoni","year":"2018","unstructured":"Marangoni E, Laurent C, Coussy F, El-Botty R, Ch\u00e2teau-Joubert S, Servely JL, et al. Capecitabine efficacy is correlated with TYMP and RB1 expression in PDX established from Triple-Negative breast cancers. Clin Cancer Research: Official J Am Association Cancer Res. 2018;24(11):2605\u201315.","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"issue":"14","key":"15495_CR43","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1039\/D0LC00288G","volume":"20","author":"Y Hou","year":"2020","unstructured":"Hou Y, Ai X, Zhao L, Gao Z, Wang Y, Lu Y, et al. An integrated biomimetic array chip for high-throughput co-culture of liver and tumor microtissues for advanced anticancer bioactivity screening. Lab Chip. 2020;20(14):2482\u201394.","journal-title":"Lab Chip"},{"issue":"5","key":"15495_CR44","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","volume":"13","author":"DN Khalil","year":"2016","unstructured":"Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, cars and combination immunotherapy. Nat Reviews Clin Oncol. 2016;13(5):273\u201390.","journal-title":"Nat Reviews Clin Oncol"},{"key":"15495_CR45","doi-asserted-by":"crossref","unstructured":"Rizzo A, Mollica V, Marchetti A, Nuvola G, Rosellini M, Tassinari E, et al. Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study. Cancers. 2022;14(17):4142.","DOI":"10.3390\/cancers14174142"},{"key":"15495_CR46","doi-asserted-by":"publisher","first-page":"116659","DOI":"10.1016\/j.biopha.2024.116659","volume":"175","author":"F Chen","year":"2024","unstructured":"Chen F, Sheng J, Li X, Gao Z, Zhao S, Hu L, et al. Unveiling the promise of PD1\/PD-L1: A new dawn in immunotherapy for cholangiocarcinoma. Biomed pharmacotherapy = Biomedecine Pharmacotherapie. 2024;175:116659.","journal-title":"Biomed pharmacotherapy = Biomedecine Pharmacotherapie"},{"issue":"3","key":"15495_CR47","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1096\/fj.201700740R","volume":"32","author":"M Wang","year":"2018","unstructured":"Wang M, Yao LC, Cheng M, Cai D, Martinek J, Pan CX, et al. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy. FASEB Journal: Official Publication Federation Am Soc Experimental Biology. 2018;32(3):1537\u201349.","journal-title":"FASEB Journal: Official Publication Federation Am Soc Experimental Biology"},{"issue":"10","key":"15495_CR48","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1136\/gutjnl-2017-315201","volume":"67","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Shuen TWH, Toh TB, Chan XY, Liu M, Tan SY, et al. Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy. Gut. 2018;67(10):1845\u201354.","journal-title":"Gut"},{"key":"15495_CR49","doi-asserted-by":"crossref","unstructured":"Sahin TK, Ayasun R, Rizzo A, Guven DC. Prognostic value of Neutrophil-to-Eosinophil ratio (NER) in cancer: A systematic review and Meta-Analysis. Cancers. 2024;16(21):3689.","DOI":"10.3390\/cancers16213689"},{"key":"15495_CR50","doi-asserted-by":"publisher","first-page":"101514","DOI":"10.1016\/j.tranon.2022.101514","volume":"25","author":"R Carloni","year":"2022","unstructured":"Carloni R, Rizzo A, Ricci AD, Federico AD, De Luca R, Guven DC, et al. Targeting tumor microenvironment for cholangiocarcinoma: opportunities for precision medicine. Transl Oncol. 2022;25:101514.","journal-title":"Transl Oncol"},{"issue":"7","key":"15495_CR51","doi-asserted-by":"publisher","first-page":"101627","DOI":"10.1016\/j.xcrm.2024.101627","volume":"5","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Li S, Zhu L, Huang M, Xie Y, Song X, et al. Personalized drug screening using patient-derived organoid and its clinical relevance in gastric cancer. Cell Rep Med. 2024;5(7):101627.","journal-title":"Cell Rep Med"},{"issue":"1","key":"15495_CR52","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s13046-022-02519-7","volume":"41","author":"S Schuth","year":"2022","unstructured":"Schuth S, Le Blanc S, Krieger TG, Jabs J, Schenk M, Giese NA, et al. Patient-specific modeling of stroma-mediated chemoresistance of pancreatic cancer using a three-dimensional organoid-fibroblast co-culture system. J Experimental Clin Cancer Research: CR. 2022;41(1):312.","journal-title":"J Experimental Clin Cancer Research: CR"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15495-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15495-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15495-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:59:38Z","timestamp":1781625578000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-15495-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15495"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15495-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,31]]},"assertion":[{"value":"16 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval and consent to participate all procedures performed in this study involving human participants and animals were approved by the Ethics Committee of the Tianjin First Central Hospital and Tianjin Tian Cheng New Drug Evaluation Co., Ltd. Written informed consent was signed by each patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"173"}}